THC:CBD spray consistently reduced MS spasticity regardless of disability level or duration
A subgroup analysis of the SAVANT trial found that nabiximols (THC:CBD spray) halved spasticity and pain severity scores across all patient subgroups, with severe spasticity patients showing the largest benefits.
Quick Facts
What This Study Found
In post hoc analysis of the SAVANT RCT, THC:CBD oromucosal spray halved mean spasticity and pain severity scores across all subgroups defined by disability level (EDSS), spasticity severity, and spasticity duration. Active treatment significantly improved spasticity from week 4 onward. Patients with severe resistant spasticity achieved the most significant therapeutic gains.
Key Numbers
THC:CBD spray halved mean spasticity and pain NRS scores in all subgroups; significant improvement from week 4 in both EDSS subgroups, severe spasticity subgroup, and both duration subgroups.
How They Did This
Post hoc subgroup analysis of the SAVANT randomized, double-blind, placebo-controlled trial of nabiximols vs. optimized first-line antispastics in resistant MS spasticity, stratified by EDSS score, spasticity severity, and spasticity duration.
Why This Research Matters
Clinicians need to know which MS patients benefit most from nabiximols. This analysis shows consistent benefit across disability levels and durations, with the strongest signals in the most severely affected patients.
The Bigger Picture
The consistency of benefit across subgroups strengthens the evidence for nabiximols in MS spasticity. Unlike many treatments that work mainly in mild cases, this one appears most effective in severe disease.
What This Study Doesn't Tell Us
Post hoc subgroup analysis (not pre-specified); single RCT dataset; subgroups may be underpowered for some comparisons; 12-week treatment period.
Questions This Raises
- ?Does the benefit persist beyond 12 weeks?
- ?Would earlier initiation of nabiximols prevent progression to severe spasticity?
Trust & Context
- Key Stat:
- Nabiximols halved spasticity scores across all disability subgroups
- Evidence Grade:
- Strong: based on a well-designed RCT, though this is a post hoc subgroup analysis.
- Study Age:
- Published 2020.
- Original Title:
- Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
- Published In:
- The International journal of neuroscience, 130(12), 1199-1205 (2020)
- Authors:
- Meuth, Sven G, Henze, Thomas(2), Essner, Ute(2), Trompke, Christiane, Vila Silván, Carlos
- Database ID:
- RTHC-02723
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does nabiximols work for all levels of MS spasticity?
Yes. The analysis found consistent benefit across mild, moderate, and severe spasticity, with the most significant gains seen in patients with severe resistant spasticity.
How quickly does nabiximols start working?
Significant improvement in spasticity scores compared to placebo was seen from week 4 of treatment onward.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02723APA
Meuth, Sven G; Henze, Thomas; Essner, Ute; Trompke, Christiane; Vila Silván, Carlos. (2020). Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.. The International journal of neuroscience, 130(12), 1199-1205. https://doi.org/10.1080/00207454.2020.1730832
MLA
Meuth, Sven G, et al. "Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.." The International journal of neuroscience, 2020. https://doi.org/10.1080/00207454.2020.1730832
RethinkTHC
RethinkTHC Research Database. "Tetrahydrocannabinol and cannabidiol oromucosal spray in res..." RTHC-02723. Retrieved from https://rethinkthc.com/research/meuth-2020-tetrahydrocannabinol-and-cannabidiol-oromucosal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.